Hansa Biopharma AB (HNSA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Douglas Tsao from H.C. Wainwright maintained a Buy rating on the stock and has a SEK143.00 price target.
Douglas Tsao has given his Buy rating due to a combination of factors that suggest a positive outlook for Hansa Biopharma AB. The company is expected to benefit from new reimbursement agreements in Spain, a significant market for transplants, and the completion of a post-approval study that previously impacted commercial patient numbers. These developments are anticipated to contribute positively to the company’s performance in the upcoming quarters.
Additionally, Tsao’s valuation of Hansa Biopharma is based on a discounted risk-adjusted revenue model, with a price target of SEK143. The model considers the probability of success for various pipeline assets, including highly sensitized kidney transplants and Goodpasture syndrome, which are in advanced stages of development. Despite some risks related to financial needs, reimbursement challenges, and regulatory hurdles, the potential for significant catalysts in 2025, such as the results from Phase 3 studies in anti-GBM disease and kidney transplantation, underpins the Buy rating.